Drug-protein binding displacement

Pharmacokinetics Drug interactions Protein binding

A drug-drug interaction mechanism where one drug displaces another from plasma protein binding sites, transiently increasing the free (unbound) fraction of the displaced drug. Despite historical concern, most displacement interactions are clinically insignificant due to compensatory increases in volume of distribution and clearance.

Mechanism and Compensation

Most highly bound drugs (warfarin 99%, phenytoin 90%, valproate 90%) are bound primarily to albumin (Site I or Site II). When a competing drug with higher affinity or higher concentration displaces the bound drug, the sequence of events is:

Free fraction increases — e.g., warfarin goes from fu 0.01 to 0.02 (doubling).
Free drug redistributes — increased free drug diffuses into peripheral tissues, expanding apparent Vd. For high-Vd drugs this is rapid and substantial.
Clearance increases — only free drug is available for CYP450 metabolism and glomerular filtration. Increased fu → increased CL.
New steady state — after redistribution, free Css = Dose × fu / (Vd × ke). Since fu increases in numerator and denominator (via CL = CL_int × fu), the net effect on free Css is often minimal.

The "warfarin-sulfonamide" historical example:

Early reports (1970s–80s) of elevated INR when sulfonamides were added to warfarin were attributed to displacement. Later analysis showed the primary mechanism was CYP2C9 inhibition by sulfonamides (which also inhibit the S-warfarin metabolising enzyme), not displacement per se. Displacement alone would have been self-limiting; combined displacement + CYP inhibition is the clinically significant combination.

~99%

Warfarin plasma binding

fu ≈ 0.01; albumin Site I

~90%

Phenytoin binding

Reduced to ~80% in uraemia

85–95%

Valproate binding

Saturable at high doses

Usually benign

Displacement alone

Compensated by Vd/CL rise

When Displacement Matters

Four conditions increase clinical significance:

Narrow therapeutic index

Warfarin, phenytoin, valproate, methotrexate — even transient free-drug elevation may cause bleeding, seizure, or toxicity.

Concurrent CYP inhibition

When the displacing drug also inhibits the metabolising enzyme (e.g., sulfonamides + warfarin: displace + inhibit CYP2C9), clearance cannot compensate.

Acute high-concentration bolus

A rapid IV injection of a displacing agent can cause a sharp, transient spike in free drug before redistribution and clearance can normalise levels.

Impaired clearance

In hepatic or renal impairment, the compensatory increase in clearance is blunted — free drug accumulates to a greater extent.

Frequently Asked Questions

Why are most protein binding displacement interactions clinically insignificant? +

When free drug increases, two compensatory mechanisms activate: (1) free drug redistributes into peripheral tissues, expanding Vd and lowering free plasma concentrations; (2) more free drug is available for metabolism and renal filtration, increasing total clearance. The combined effect usually restores free Css to near its original level within hours. The transient peak is brief and rarely causes harm except for very narrow therapeutic index drugs.

When is protein binding displacement clinically important? +

Displacement is most significant when: the drug has a narrow therapeutic index (warfarin, phenytoin); the displacing drug also inhibits metabolism; the displaced drug has a low volume of distribution limiting redistribution; clearance is impaired by organ dysfunction; or the displacing drug is given as a rapid high-concentration IV bolus.